Xencor Inc (XNCR)
Debt-to-equity ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 677,611 | 668,796 | 727,496 | 733,504 | 572,444 |
Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $677,611K
= 0.00
Xencor Inc has consistently maintained a debt-to-equity ratio of 0.00 from December 31, 2020, to December 31, 2024. This indicates that the company has not utilized any debt to finance its operations and has relied solely on equity for funding. A debt-to-equity ratio of 0.00 generally signifies a low financial risk, as there is no debt that needs to be repaid, and the company's operations are supported by its equity. It suggests that Xencor Inc has a strong financial position and a healthy balance sheet with no significant debt burdens.
Peer comparison
Dec 31, 2024
Company name
Symbol
Debt-to-equity ratio
Xencor Inc
XNCR
0.00
Abbott Laboratories
ABT
0.00
AbbVie Inc
ABBV
0.00
ACADIA Pharmaceuticals Inc
ACAD
0.00
Alkermes Plc
ALKS
0.00
Amphastar P
AMPH
0.84
ANI Pharmaceuticals Inc
ANIP
0.00
Arcus Biosciences Inc
RCUS
0.00
Biomarin Pharmaceutical Inc
BMRN
0.11
Bristol-Myers Squibb Company
BMY
2.91
Catalyst Pharmaceuticals Inc
CPRX
0.00